Phase I ,Single Center, Open-labeling, Single and Dose-escalating Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of Oral Novel ERa36 Modifier Icaritin in Advanced Breast Patients.
Phase of Trial: Phase I
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Icaritin (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions
- 03 Jun 2014 Interim results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
- 27 Jan 2011 New trial record